AEterna Zentaris Inc

Find Ratings Reports
AEZS : NASDAQ : Health Care
$2.13 | %
Today's Range: 2.11 - 2.27
Avg. Daily Volume: 2839000.0
09/22/17 - 3:59 PM ET

Financial Analysis

AETERNA ZENTARIS INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. AETERNA ZENTARIS INC is extremely liquid. Currently, the Quick Ratio is 3.52 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 50.38% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)0.240.1
EBITDA ($mil)0.0-7.14
EBIT ($mil)-6.68-7.18
Net Income ($mil)-2.55-7.01

Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)13.9326.17
Total Assets ($mil)24.5137.07
Total Debt ($mil)0.00.0
Equity ($mil)4.499.05

Profitability Q2 FY17 Q2 FY16
Gross Profit Margin-2748.56-7432.29
EBITDA Margin0.0-7432.29
Operating Margin-2748.56-7483.33
Sales Turnover0.040.02
Return on Assets-85.51-97.09
Return on Equity-466.62-399.16
Debt Q2 FY17 Q2 FY16
Current Ratio3.715.04
Interest Expense0.00.0
Interest Coverage0.00.0

Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)14.659.94
Div / share0.00.0
Book value / share0.310.91
Institutional Own % n/a n/a
Avg Daily Volume2739509.0436780.0


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 6.30 indicates a significant premium versus the S&P 500 average of 3.10 and a significant discount versus the industry average of 12.14. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, AETERNA ZENTARIS INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AEZS NM Peers 39.88   AEZS NM Peers 27.93

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

AEZS's P/E is negative making this valuation measure meaningless.


Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AEZS's P/CF is negative making the measure meaningless.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
AEZS NA Peers 25.67   AEZS NA Peers 0.50

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AEZS 6.30 Peers 12.14   AEZS 81.03 Peers 10.47

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AEZS is trading at a significant discount to its peers.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

AEZS is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AEZS 26.18 Peers 94.57   AEZS 75.69 Peers 233.22

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AEZS is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

AEZS significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades